LSD1-INHIBITOREN

European patent · EP3397616 · In force

Register entry

Publication number
EP3397616
Application number
EP16805585
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Nov 3, 2016
Published
Nov 7, 2018
Granted
Jun 10, 2020
Protection ends at the latest
Nov 2, 2036
Next annual fee due
Nov 30, 2026
IPC classes
C07D 205/04 (2006.01)
C07D 265/10 (2006.01)
C07D 211/58 (2006.01)
C07D 213/64 (2006.01)
A61K 31/4468 (2006.01)
A61K 31/445 (2006.01)
A61P 35/00 (2006.01)
Priority
US 201562272082 P 29.12.2015
US 201662295369 P 15.02.2016
PCT application
PCT/US2016/060379 03.11.2016
PCT publication
WO2017/116558 06.07.2017
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Dec 1, 2025

    Change

    Published in Swissreg on 01.12.2025

  2. Dec 1, 2024

    Change

    Published in Swissreg on 01.12.2024

  3. Dec 1, 2023

    Change

    Published in Swissreg on 01.12.2023

  4. Dec 1, 2022

    Change

    Published in Swissreg on 01.12.2022

  5. Sep 11, 2020

    Agent entered

    Representative
    MICHELI & CIE SA, 122, Rue de Genève, Case postale 61, 1226 Thônex

    Published in Swissreg on 11.09.2020

  6. Jun 10, 2020

    Granted

    Published in Swissreg on 10.06.2020

Parties

Holder

Mirati Therapeutics, Inc.

9393 Towne Centre Drive Suite 200, San Diego, CA 92121, US

Agent

MICHELI & CIE SA

122, Rue de Genève Case postale 61, 1226 Thônex

Inventor

MARX, Matthew, Arnold

San Diego, CA 92127, US

GALEMMO, Robert, Anthony, Jr.

San Francisco, CA 94111, US

CHRISTENSEN, James, Gail

San Diego, CA 92130, US

VAISBURG, Arkadii

Kirkland, QC H9J 2X2, CA

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.